Pfizer's Lorbrena Sets New Benchmark in Treating Advanced Lung Cancer

Five-year trial results show unprecedented survival rates and reduced brain metastasis in ALK-positive non-small cell lung cancer patients.

Lorbrena helped 60% of patients live progression-free for five years, compared to 8% with older treatments.
The drug significantly reduces the risk of cancer spreading to the brain, a common issue in ALK-positive lung cancer.
Lorbrena is effective at crossing the blood-brain barrier, enhancing its ability to treat brain metastasis.
Patients experienced manageable side effects, though cognitive and mood changes were noted.
Experts hail the results as a major advancement in lung cancer treatment, potentially setting a new standard of care.